Stocktoria
MADRIGAL PHARMACEUTICALS, INC. MDGL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2007-02-06
MADRIGAL PHARMACEUTICALS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $958.4M | $180.1M | $0 | $0 | $0 |
| SG&A expense | $813.8M | $435.1M | $108.1M | $48.1M | — |
| Operating income | -$300.1M | -$497.9M | -$380.5M | -$293.6M | -$242.5M |
| Interest expense | — | — | $12.7M | $4.0M | $0 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$288.3M | -$465.9M | -$373.6M | -$295.4M | -$241.8M |
| EPS (diluted) | $-10.15 | $-17.31 | $-17.33 | $-17.23 | $-14.63 |
| Operating cash flow | -$189.6M | -$455.6M | -$324.2M | -$224.9M | -$183.9M |
| Free cash flow | -$190.0M | -$457.0M | -$325.7M | -$225.1M | -$184.1M |
| Cash & equivalents | $198.7M | $100.0M | $99.9M | $331.5M | $36.3M |
| Inventory | $74.8M | $34.1M | $0 | — | — |
| Total assets | $1.3B | $1.0B | $640.5M | $362.6M | $273.3M |
| Total liabilities | $656.9M | $287.9M | $235.2M | $165.2M | $77.2M |
| Shareholders' equity | $602.7M | $754.4M | $405.3M | $197.4M | $196.1M |
Source: SEC EDGAR filings · CIK 0001157601 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.